OptiNose Net Worth
OptiNose Net Worth Breakdown | OPTN |
OptiNose Net Worth Analysis
OptiNose's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including OptiNose's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of OptiNose's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform OptiNose's net worth analysis. One common approach is to calculate OptiNose's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares OptiNose's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing OptiNose's net worth. This approach calculates the present value of OptiNose's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of OptiNose's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate OptiNose's net worth. This involves comparing OptiNose's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into OptiNose's net worth relative to its peers.
Enterprise Value |
|
To determine if OptiNose is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OptiNose's net worth research are outlined below:
| OptiNose generated a negative expected return over the last 90 days | |
| OptiNose has high historical volatility and very poor performance | |
| OptiNose has some characteristics of a very speculative penny stock | |
| OptiNose has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 70.99 M. Net Loss for the year was (35.48 M) with profit before overhead, payroll, taxes, and interest of 67.01 M. | |
| OptiNose currently holds about 78.26 M in cash with (20.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| OptiNose has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Optinose to Announce Q3 2024 Financial Results with Investor Call - MSN |
OptiNose uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in OptiNose. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to OptiNose's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know OptiNose's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OptiNose is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OptiNose backward and forwards among themselves. OptiNose's institutional investor refers to the entity that pools money to purchase OptiNose's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Velan Capital Investment Management Lp | 2024-06-30 | 2.5 M | Easterly Investment Partners. | 2024-09-30 | 2.4 M | Stonepine Capital Management Llc | 2024-06-30 | 2.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Prescott Group Capital Management Llc | 2024-09-30 | 1.3 M | Rice Hall James & Associates, Llc | 2024-09-30 | 1.1 M | Gmt Capital Corp | 2024-06-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | J. Goldman & Co Lp | 2024-09-30 | 675 K | Fmr Inc | 2024-09-30 | 16.5 M | Mvm Partners Llc | 2024-09-30 | 14.6 M |
Follow OptiNose's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 79.88 M.Market Cap |
|
Project OptiNose's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | 0.33 | 0.35 | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | 0.41 | 0.43 |
When accessing OptiNose's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures OptiNose's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OptiNose's profitability and make more informed investment decisions.
Evaluate OptiNose's management efficiency
OptiNose has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.505) %, meaning that it created substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities. At this time, OptiNose's Return On Capital Employed is very stable compared to the past year. As of the 26th of November 2024, Return On Equity is likely to grow to 0.43, while Return On Tangible Assets are likely to drop (0.35). At this time, OptiNose's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Other Current Assets is likely to grow to about 4.2 M, though Net Tangible Assets are likely to grow to (61.9 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.77) | (0.73) | |
| Tangible Book Value Per Share | (0.77) | (0.73) | |
| Enterprise Value Over EBITDA | (13.03) | (12.38) | |
| Price Book Value Ratio | (1.67) | (1.75) | |
| Enterprise Value Multiple | (13.03) | (12.38) | |
| Price Fair Value | (1.67) | (1.75) | |
| Enterprise Value | 202.6 M | 133.5 M |
Understanding the operational decisions made by OptiNose management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.5447 | Revenue 75.7 M | Quarterly Revenue Growth 0.031 | Revenue Per Share 0.553 | Return On Equity (10.51) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OptiNose insiders, such as employees or executives, is commonly permitted as long as it does not rely on OptiNose's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OptiNose insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OptiNose time-series forecasting models is one of many OptiNose's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary OptiNose's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
OptiNose Earnings per Share Projection vs Actual
OptiNose Corporate Management
| Anthony Krick | Vice Officer | Profile | |
| Michele MBA | VP CFO | Profile | |
| Terence Kohler | Chief Officer | Profile | |
| Paul Spence | Chief Officer | Profile | |
| John Messina | Sr Affairs | Profile | |
| Karen Brophy | Chief Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 0.553 | Quarterly Revenue Growth 0.031 | Return On Assets (0.10) | Return On Equity (10.51) |
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.